Phathom Pharmaceuticals Inc (NASDAQ:PHAT) has a beta value of 0.62 and has seen 1.22 million shares traded in the last trading session. The company, currently valued at $631.21M, closed the last trade at $9.34 per share which meant it lost -$0.11 on the day or -1.16% during that session. The PHAT stock price is -111.03% off its 52-week high price of $19.71 and 35.01% above the 52-week low of $6.07. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.87 million shares traded. The 3-month trading volume is 1.34 million shares.
The consensus among analysts is that Phathom Pharmaceuticals Inc (PHAT) is Buy stock at the moment, with a recommendation rating of 1.25. 2 analysts rate the stock as a Sell, while 0 rate it as Overweight. 2 out of 10 have rated it as a Hold, with 6 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -1.06.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Phathom Pharmaceuticals Inc (NASDAQ:PHAT) trade information
Sporting -1.16% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the PHAT stock price touched $9.34 or saw a rise of 6.41%. Year-to-date, Phathom Pharmaceuticals Inc shares have moved 2.30%, while the 5-day performance has seen it change 6.38%. Over the past 30 days, the shares of Phathom Pharmaceuticals Inc (NASDAQ:PHAT) have changed -42.38%. Short interest in the company has seen 17.45 million shares shorted with days to cover at 17.41.
Wall Street analysts have a consensus price target for the stock at $27, which means that the shares’ value could jump 65.41% from current levels. The projected low price target is $12.0 while the price target rests at a high of $35.0. In that case, then, we find that the current price level is -274.73% off the targeted high while a plunge would see the stock gain -28.48% from current levels.
Phathom Pharmaceuticals Inc (PHAT) estimates and forecasts
Figures show that Phathom Pharmaceuticals Inc shares have underperformed across the wider relevant industry. The company’s shares have lost -11.05% over the past 6 months, with this year growth rate of -71.54%, compared to 18.00% for the industry. Revenue growth from the last financial year stood is estimated to be 7,431.30%.
6 analysts offering their estimates for the company have set an average revenue estimate of 25.77M for the current quarter. 3 have an estimated revenue figure of 28.02M for the next ending quarter. Year-ago sales stood 682k and 1.91M respectively for this quarter and the next, and analysts expect sales will grow by 3,678.74% for the current quarter and 7,431.30% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -137.06% over the past 5 years.
PHAT Dividends
Phathom Pharmaceuticals Inc is expected to release its next earnings report in December this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Phathom Pharmaceuticals Inc (NASDAQ:PHAT)’s Major holders
Insiders own 7.70% of the company shares, while shares held by institutions stand at 109.32% with a share float percentage of 118.44%. Investors are also buoyed by the number of investors in a company, with Phathom Pharmaceuticals Inc having a total of 199.0 institutions that hold shares in the company. The top two institutional holders are FRAZIER LIFE SCIENCES MANAGEMENT, L.P. with over 10.11 million shares worth more than $104.13 million. As of 2024-06-30, FRAZIER LIFE SCIENCES MANAGEMENT, L.P. held 17.3189% of shares outstanding.
The other major institutional holder is MEDICXI VENTURES MANAGEMENT (JERSEY) LTD, with the holding of over 7.46 million shares as of 2024-06-30. The firm’s total holdings are worth over $76.89 million and represent 12.788% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are PGIM Jennison Health Sciences Fd and Fidelity Rutland Square Tr II-Strategic Advisers U.S. Total Stock Fd . As of Sep 30, 2024 , the former fund manager holds about 2.89% shares in the company for having 1.97 shares of worth $18.43 million while later fund manager owns 1.75 shares of worth $16.34 million as of Aug 31, 2024 , which makes it owner of about 2.56% of company’s outstanding stock.
